Drug Profile


Alternative Names: ManNAc

Latest Information Update: 25 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Human Genome Research Institute
  • Developer Escala Therapeutics; National Center for Advancing Translational Sciences; National Human Genome Research Institute; National Institutes of Health (USA)
  • Class Hexosamines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nonaka distal myopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Kidney disorders; Nonaka distal myopathy

Most Recent Events

  • 11 Dec 2015 Escala Therapeutics plans a phase I trial for Kidney disorders (Fortress Biotech pipeline)
  • 01 Dec 2015 Phase-I clinical trials in Kidney disorders (Treatment-experienced) in USA (PO) (NCT02639260)
  • 25 Aug 2015 New Zealand Pharmaceuticals receives patent allowance for DEX M74 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top